Autor(es):
Diculescu, Victor Constantin 
; Vivan, Marilene ; Brett, Ana Maria Oliveira
Data: 2006
Identificador Persistente: http://hdl.handle.net/10316/8272
Origem: Estudo Geral - Universidade de Coimbra
Detalhes do Documento
Voltammetric Behavior of Antileukemia Drug Glivec. Part III: In Situ DNA Oxidat...
Descrição
Glivec is a relatively small molecule with activity against the protein tyrosine kinase, a protein expressed by all patients with chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation of its activity against other types of tumor. As a result, there is an ongoing need for clarification of glivec pharmacokinetics so that issues such as drug-biomolecular complex interactions can be understood. http://dx.doi.org/10.1002/elan.200603602
Glivec is a relatively small molecule with activity against the protein tyrosine kinase, a protein expressed by all patients with chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation of its activity against other types of tumor. As a result, there is an ongoing need for clarification of glivec pharmacokinetics so that issues such as drug-biomolecular complex interactions can be understood. http://dx.doi.org/10.1002/elan.200603602
Tipo de Documento
Artigo
Idioma Inglês
Idioma Inglês
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||